Wednesday, October 11, 2017

FDA due to rule by April 17, 2018

The U.S. Food and Drug Administration has set the calendar for its review of KRN23/burosumab, the promising new treatment for XLH, and granted "priority review" status that will expedite the process. A decision is due from the FDA by April 17, 2018.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.